Increased epithelial galectin‐13 expression associates with eosinophilic airway inflammation in asthma
- 2 June 2021
- journal article
- research article
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 51 (12) , 1566-1576
Abstract
Background: Airway eosinophilic inflammation is a central feature in asthma which is mainly driven by type 2 response. The expression of galectin‐13 was up‐regulated in a parasitic infection model which is also characterized by type 2 immune response. We hypothesized that galectin‐13 may be involved in airway eosinophilic inflammation in asthma.Objective: To unveil the role of galectin‐13 in asthma airway inflammation.Methods: We measured galectin‐13 expressions in bronchial brushings, sputum, and plasma of asthma patients (n = 54) and healthy controls (n = 15), and analysed the correlations between galectin‐13 expression and airway eosinophilia. We used human bronchial epithelial cell line 16HBE to investigate the possible mechanism by which galectin‐13 participates in eosinophilic inflammation.Results: The expression of galectin‐13 was markedly increased in subjects with asthma compared to controls. Epithelial galectin‐13 mRNA levels in asthmatic subjects were strongly correlated with eosinophilic airway inflammation (the percentage of sputum eosinophils, the number of eosinophils in bronchial submucosa and FeNO) and the expression of Th2 signature genes (CLCA1, POSTN and SERPINB2). Inhaled corticosteroid (ICS) treatment reduced plasma galectin‐13 levels, and baseline plasma galectin‐13 levels reflect the response to ICS treatment. In cultured 16HBE cells, knockdown of galectin‐13 suppressed IL‐13‐stimulated MCP‐1 and eotaxin‐1 expression by inhibiting the activation of EGFR and ERK.Conclusions & Clinical Relevance: Galectin‐13 is a novel marker for airway eosinophilia in asthma, and may contribute to allergic airway eosinophilic inflammation by up‐regulating the expression of MCP‐1 and eotaxin‐1. Plasma galectin‐13 levels may be useful for predicting responses to ICS treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81800026, 81670019, 91742108)
This publication has 36 references indexed in Scilit:
- Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical TrialsBiomolecules, 2020
- AsthmaThe Lancet, 2018
- Intelectin contributes to allergen-induced IL-25, IL-33, and TSLP expression and type 2 response in asthma and atopic dermatitisMucosal Immunology, 2017
- Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesisCurrent Opinion in Immunology, 2017
- Tissue- and cell-specific localization of galectins, β-galactose-binding animal lectins, and their potential functions in health and diseaseAnatomical Science International, 2016
- The immunology of asthmaNature Immunology, 2014
- Salivary Inflammatory Mediator Profiling and Correlation to Clinical Disease Markers in AsthmaPLOS ONE, 2014
- The Eotaxin Chemokines and CCR3 Are Fundamental Regulators of Allergen-Induced Pulmonary EosinophiliaThe Journal of Immunology, 2005
- Animal lectins: a historical introduction and overviewBiochimica et Biophysica Acta (BBA) - General Subjects, 2002